Skip to main content

Grafa News and Videos — Page 1558

Latest

Grafa

Gilead to acquire Tubulis for $5B to accelerate next-generation cancer therapies

Gilead Sciences (NASDAQ:GILD) announced on April 7, 2026, that it has entered into a definitive agreement to acquire Tubulis GmbH, a private German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs).

Read more: Gilead to acquire Tubulis for $5B to accelerate next-generation cancer therapies
Grafa

Jaguar Health reports Q4 2025 results and highlights $16M strategic cash infusion

Jaguar Health (NASDAQ:JAGX), a commercial-stage pharmaceutical company focused on gastrointestinal products, released its consolidated financial results for the fourth quarter and full year ended December 31, 2025, on April 7, 2026.

Read more: Jaguar Health reports Q4 2025 results and highlights $16M strategic cash infusion
Grafa

FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has accepted its Formal Dispute Resolution Request (FDRR) regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).

Read more: FDA grants Outlook Therapeutics formal dispute resolution meeting for ONS-5010
Grafa
Technology

Bit Digital discloses March 2026 Ethereum treasury and staking performance

Bit Digital (NASDAQ:BTBT), a high-performance computing and digital asset mining company, has released its monthly treasury and staking update for March 2026, highlighting a significant Ethereum position and active yield-generation strategy.

Read more: Bit Digital discloses March 2026 Ethereum treasury and staking performance
Grafa

Halozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology

Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) announced a global exclusive collaboration and license agreement on April 7, 2026, aimed at leveraging Halozyme’s proprietary Hypercon™ microparticle technology to transform the delivery of biologic therapies.

Read more: Halozyme and Vertex sign global license deal to advance Hypercon™ microparticle technology
Grafa

Alzamend Neuro announces preliminary brain imaging data for lithium candidate AL001

Alzamend Neuro (NASDAQ:ALZN), a clinical-stage biopharmaceutical company focused on developing novel products for neurological disorders, reported preliminary pharmacodynamic data on April 7, 2026, from a healthy-subject study evaluating its lead candidate, AL001.

Read more: Alzamend Neuro announces preliminary brain imaging data for lithium candidate AL001
Grafa
Technology

Booz Allen Hamilton finalizes acquisition of Defy Security to acale AI-driven cyber solutions

Booz Allen Hamilton (NYSE:BAH) announced on April 7, 2026, the successful completion of its acquisition of Defy Security, a move aimed at consolidating its position as a dominant provider of high-speed, tech-enabled cybersecurity services for both commercial and government sectors.

Read more: Booz Allen Hamilton finalizes acquisition of Defy Security to acale AI-driven cyber solutions
Grafa
Technology

ASML shares fall as U.S. lawmakers propose further curbs on China exports

Shares of ASML Holding (NYSE:ASML) declined on Tuesday as investors reacted to a new legislative proposal from U.S. lawmakers that could significantly tighten restrictions on the company’s ability to sell and service advanced chipmaking equipment in China.

Read more: ASML shares fall as U.S. lawmakers propose further curbs on China exports

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift